Hypothesis

Restoration of gut‑derived butyrate signaling through the microglial GPR109A receptor reverses prefrontal cortical synaptic pruning deficits that underlie treatment‑resistant depression (TRD).

Mechanistic Rationale

• Butyrate, a short‑chain fatty acid produced by anti‑inflammatory bacteria, inhibits histone deacetylases (HDACs) and activates the G‑protein coupled receptor GPR109A on microglia (1).
• HDAC inhibition promotes an anti‑inflammatory microglial phenotype, reducing NLRP3 inflammasome activation and downstream cytokine release (2).
• GPR109A activation shifts microglia from a phagocytic, synapse‑eliminating state to a supportive state, decreasing complement C1q‑mediated synaptic tagging in the prefrontal cortex (3).
• In TRD, post‑mortem and imaging studies show heightened microglial activation and reduced synaptic density in the dorsolateral prefrontal cortex, correlating with low fecal butyrate levels (4).
• Therefore, boosting butyrate‑GPR109A signaling should normalize microglial function, preserve synapses, and improve depressive symptoms.

Testable Predictions

1. Participants with TRD who receive a targeted butyrate‑producing probiotic (e.g., Clostridium butyricum MIYAIRI 588) plus a low‑dose HDAC inhibitor (e.g., sodium butyrate) will show a significant increase in fecal butyrate concentration compared with placebo.
2. Elevated fecal butyrate will correlate with increased microglial GPR109A activation, measurable via peripheral blood monocyte GPR109A expression or PET imaging with a GPR109A‑specific tracer.
3. Enhanced GPR109A signaling will be associated with reduced prefrontal cortical synaptic loss, assessed by magnetic resonance spectroscopy (MRS) of glutamate/glutamine cycling or synaptic vesicle glycoprotein 2A (SV2A) PET.
4. Clinical improvement (≥50% reduction in HAM‑D score) will occur only in the subgroup demonstrating both increased butyrate and microglial GPR109A engagement.

Experimental Design

• Study: Double‑blind, randomized, placebo‑controlled trial.
• Population: 120 adults with TRD (failed ≥2 antidepressant trials), aged 18‑65.
• Arms: (A) Butyrate‑producing probiotic + sodium butyrate (500 mg/day); (B) Probiotic alone; (C) Placebo.
• Duration: 16 weeks (to allow microbiome remodeling and neurobiological changes).
• Measurements: Baseline and weekly fecal SCFA quantification (GC‑MS); monthly blood monocyte GPR109A mRNA (qPCR); optional [11C]‑PBR28 PET for microglial activation at weeks 0 and 8; SV2A PET at weeks 0 and 16; HAM‑D and MADRS scores every 2 weeks.
• Analysis: Mixed‑effects models testing interaction between treatment, butyrate level, GPR109A activation, and synaptic marker change on depression scores.

Potential Outcomes and Falsifiability

• Support: A significant dose‑response relationship where increased fecal butyrate → higher microglial GPR109A activation → preserved SV2A binding → greater mood improvement, with the combined arm outperforming monotherapies.
• Falsification: If the combined arm fails to raise fecal butyrate above placebo, or if elevated butyrate does not increase microglial GPR109A activation or synaptic markers, or if clinical improvement occurs without these biochemical changes, the hypothesis is refuted.

This framework integrates microbial metabolism, immune signaling, and synaptic physiology, offering a precise, falsifiable target for next‑generation psychobiotic development in TRD.